Data on the investigative, temporary gut liner, EndoBarrier, showed improvement in weight, A1c, fatty liver, and need for insulin, and the effect persisted for up to 2 years after its removal.
A new International Diabetes Federation position statement calls for improved prediction of type 2 diabetes in high-risk individuals using a 1-hour glucose tolerance test.
Shares in Zealand Pharma soared 34% on Monday after an experimental weight-loss drug it is developing with Boehringer Ingelheim yielded what they called "groundbreaking".